Project Grant R01AG084676

Award Date 9/20/24
Completion Date 8/31/29
Dollars Obligated $1.8M
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
This Project Grant award, valued at $816,554.00, was provided by the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279). The award aims to develop and validate a mouse model of chemotherapy-induced peripheral neuropathy (CIPN) that replicates tumor growth, surgical resection, and treatment with an oxaliplatin-based chemotherapy regimen. The research will assess the impact of surgery and tumor growth on the...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), provides $1,239,420 to the University of Maryland, Baltimore (UMB) to conduct a longitudinal observational study on the role of interoception (the brain's processing of internal bodily sensations) in chemotherapy-induced peripheral neuropathy (CIPN) in 120 patients with breast or gastrointestinal cancer. The study, which will also include 60 age-matched...
This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $979,000.00 to the Beckman Research Institute of the City of Hope to conduct a randomized pilot study on a blended e-health intervention for fear of progression (FOP) in patients with advanced gynecologic cancer. The study will test the feasibility and efficacy of the intervention, which combines group videoconferencing sessions, web-based self-study modules, and nurse/social...
The National Institute on Aging, part of the Department of Health and Human Services' National Institutes of Health, awarded $3,387,438 under the Aging Research program (CFDA 93.866) to The Ohio State University Office of Sponsored Programs on September 19, 2022. The three-year project grant aims to develop and test a novel neuroprotective agent, TAT-M2NX, to provide both acute and sustained synaptic protection following acute ischemic stroke. The research seeks to characterize the agent's...
This Project Grant award, with funding of $181,448.00 from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research), supports research to determine whether the drug dapansutrile, a selective NLRP3 inflammasome inhibitor, can alleviate and prevent chemotherapy-induced peripheral neuropathy (CIPN) in mouse models. The research will evaluate the effects of dapansutrile administration in mice treated with the chemotherapy drug paclitaxel, both in naïve and tumor-bearing animals. The...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $676,731 to Arizona State University to identify specific aspects of balance and reactive stepping that are related to falls in people with Parkinson's disease (PD). The goals of this 5-year project are to: Assess the relationship between reactive balance, standing balance, and prospectively measured falls in 100 individuals with PD at risk for falls. This will identify the critical balance...
This federal Project Grant award, R01CA273001, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The $402,874 award will fund research at the University of Texas Medical Branch at Galveston (UTMB) to investigate the mechanisms underlying paclitaxel-induced peripheral neuropathy (PIPN), a significant adverse effect experienced by cancer patients receiving paclitaxel infusion. The research aims to determine if the acute over-excitation...
The National Institute on Aging (NIA) awarded a $227,740 Project Grant (CFDA 93.866 - Aging Research) to the University of Florida to investigate the effects of transcutaneous spinal direct current stimulation (tsDCS) as an adjunct therapy to dynamic balance training in older adults with balance and walking deficits. The study aims to assess whether active tsDCS combined with balance training can enhance practice-related gains and retention in balance and walking performance, and whether this is...
This federal Project Grant award, totaling $5,666,172, was issued by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279). The award aims to study the role of Schwann cell dysfunction and signaling pathways in the development of chemotherapy-induced painful peripheral neuropathy (CIPPN). Key objectives include examining the impact of peroxisome proliferator-activated receptor gamma (PPARγ) and low-density lipoprotein...
This $804,795 Project Grant was awarded on September 18, 2024 by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The funding supports a comprehensive research project investigating the neural mechanisms underlying the relationship between gait and cognitive function in individuals with subjective cognitive decline and a family history of Alzheimer's disease. The project aims to determine how declines in vestibular system function and...

The National Institute on Aging (NIA) awarded a $1,832,910 Project Grant (CFDA 93.866) to The Ohio State University to conduct a multi-center, Phase II randomized clinical trial investigating the use of adapted Argentine tango dance as a non-pharmacological treatment for chemotherapy-induced neuropathy in breast cancer survivors. The project, titled "DANCE-BASED AVENUES TO ADVANCE NONPHARMACOLOGIC TREATMENT OF CHEMOTHERAPY EFFECTS (DAANCE): A MULTICENTER TRIAL," aims to evaluate the impact of tango dance on patient-reported sensation, dual-task performance, neuromotor control, falls incidence, and patient-reported outcomes. The study will also explore the treatment effects on biomarkers of neurotoxicity and inflammation, as well as cognitive load. Yale University was awarded a $137,819 sub-grant to serve as a co-lead investigator and oversee clinical recruitment, study execution, and biomarker analysis. The project period runs from September 20, 2024, to August 31, 2029.

Generated 7/8/25, 1:59 AM